84539-22-0

Basic information

• Product Name: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE
• Synonyms: 4-(5-BROMO-PYRIMIDIN-2-YL)-MORPHOLINE;5-BROMO-2-(4-MORPHOLINO)-PYRIMIDINE;5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE;2-Morpholino-5-bromopyrimidine
• CAS NO: 84539-22-0
• Molecular Formula: C₈H₁₀BrN₃O
• Molecular Weight: 244.09
• Product Categories: Organohalides;Pyrimidine
• Mol File: 84539-22-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 125.0-127.7 °C
• Boiling Point: 382.815oC at 760 mmHg
• Flash Point: 185.32oC
• Appearance: White to off-white/Crystalline Powder
• Density: 1.571g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C
• PKA: 3.23±0.42(Predicted)
• CAS DataBase Reference: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(84539-22-0)
• EPA Substance Registry System: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(84539-22-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 84539-22-0(Hazardous Substances Data)

Usage

Description

5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE, also known as 4-(5-Bromopyrimidin-2-yl)morpholine, is an organic compound that serves as a key intermediate in the synthesis of various chemical compounds. It is characterized by the presence of a bromo substituent on the pyrimidine ring and a morpholine group, which contributes to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE is used as a key intermediate in the synthesis of carbamimidoylcarbamate derivatives, which are novel vascular adhesion protein-1 (VAP-1) inhibitors. VAP-1 is an enzyme involved in the inflammatory process and has been implicated in various diseases, including diabetes, atherosclerosis, and asthma. By inhibiting VAP-1, these carbamimidoylcarbamate derivatives have the potential to treat these conditions and improve patient outcomes.

InChI:InChI=1/C8H10BrN3O/c9-7-5-10-8(11-6-7)12-1-3-13-4-2-12/h5-6H,1-4H2

Upstream product

• 57356-66-8 4-(pyrimidin-2-yl)morpholine 
• 37828-58-3 lithium morpholide 
• 183438-24-6 5-bromo-2-iodopyrimidine 
• 110-91-8 morpholine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 870521-33-8 [2-(morpholin-4-yl)pyrimidin-5-yl]boronic acid 

Relevant articles and documents

Room-Temperature Amination of Chloroheteroarenes in Water by a Recyclable Copper(II)-Phosphaadamantanium Sulfonate System

Buchwald-Hartwig amination of chloroheteroarenes has been a challenging synthetic process, with very few protocols promoting this important transformation at ambient temperature. The current report discusses about an efficient copper-based catalytic system (Cu/PTABS) for the amination of chloroheteroarenes at ambient temperature in water as the sole reaction solvent, a combination that is first to be reported. A wide variety of chloroheteroarenes could be coupled efficiently with primary and secondary amines as well as selected amino acid esters under mild reaction conditions. Catalytic efficiency of the developed protocol also promotes late-stage functionalization of active pharmaceutical ingredients (APIs) such as antibiotics (floxacins) and anticancer drugs. The catalytic system also performs efficiently at a very low concentration of 0.0001 mol % (TON = 980,000) and can be recycled 12 times without any appreciable loss in activity. Theoretical calculations reveal that the π-acceptor ability of the ligand PTABS is the main reason for the appreciably high reactivity of the catalytic system. Preliminary characterization of the catalytic species in the reaction was carried out using UV-VIS and ESR spectroscopy, providing evidence for the Cu(II) oxidation state.

LDHA ACTIVITY INHIBITORS

The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suit

BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2

The present invention directs to a compound represented by formula (I).